The nice people
at Transfusion News sent their update today. Whilst more relevant to me than
yesterday’s missive, it is still a tad vague…
Acute Normovolemic Hemodilution Reduces Transfusions in Patients Undergoing Cardiac Surgery
 | | March 15, 2023 | | Approximately
one to two million cardiac surgery operations are performed worldwide
each year accounting for about 80% of all surgical blood use. Recently,
patient blood management guidelines endorse acute normovolemic
hemodilution (ANH) for use during cardiac surgery in which part of the
patient’s blood is removed and replaced with IV fluid prior to or during
the surgery. [Read More] |
|
 | Bio-Rad
wants to better understand the Transfusion Medicine market and help
provide educational, performance, and workflow content to our shared
community. Would you like to be part of an Advisory Board or become a
key opinion leader and speaker?
Have you been
wanting to complete a study, write a paper, create an AABB poster, or
test that theory that you have not had the time or resources to
complete? No matter your current vendor, Bio-Rad wants to partner with
you! [Learn More] |
|
 | |
| Join Transfusion News Associate Editors Daniela Hermelin and Monica Pagano on Twitter Space this Friday March 17 at 10:30 AM ET
for a #Blooducation Baristas live event. They will be joined by Dan
Waxman and Kirsten Alcorn to discuss the topic of directed donations and
Covid-19 vaccinated donors, blood safety and patient autonomy. [Set a reminder to join us] |
|
 | | March 8, 2023 | | Hemophilia
B is a rare, X-linked bleeding disorder caused by partial or complete
deficiency of clotting factor IX. Currently, the standard of care for
these patients is prophylactic intravenous factor IX injections. New
results for a phase 3 adeno-associated viral (AAV) gene therapy
treatment, however, were recently published in The New England Journal
of Medicine. [Read More] |
|
No comments:
Post a Comment